Your Source for Venture Capital and Private Equity Financings

Sonoma Biotherapeutics Inks $265M Series B

2021-08-04
SOUTH SAN FRANCISCO, CA, Sonoma Biotherapeutics, an immune tolerance company, has announced an oversubscribed $265 million Series B financing.
Sonoma Biotherapeutics, an immune tolerance company focused on the development of regulatory T cell (Treg) therapies, has announced an oversubscribed $265 million Series B financing.

The round was led by Ally Bridge Group, with participation from new investors including ArrowMark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management & Research Company LLC, Frazier Healthcare Partners, GV, Janus Henderson Investors, Mirae Asset, NS Investment, Osage University Partners, Piper Heartland Healthcare Capital, Vertex Ventures HC and an undisclosed global investment fund.

Existing investors also supported this financing, including 8VC, ARCH Venture Partners, Alexandria Venture Investments, the JDRF T1D Fund, LifeForce Capital, Lilly Asia Ventures Biosciences and Octagon Capital. Since its founding in 2019, Sonoma Bio has raised more than $335 million.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading